Clinical trial · Interventional
Treatment of Malignant Strictures in Esophagus and Gastroesophageal Junction With Covered or Partially Covered Stent.
The Importance of Stent Design
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Self expandable stent (SEMS) constitutes the main palliative treatment in advanced esophageal cancer. The palliative effect of SEMS is immediate when it comes to relief of dysphagia. The duration of this effect is however questionable. The design of SEMS can be of importance since the device can dislodge and as a consequence of that dysphagia recur. The hypothesis has therefore been formulated that a partially covered SEMS is associated with less tendency to dislocate as compared to those SEMS, recently developed, which are covered through their entire length.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Gastro Esophageal Junction | Esophageal Neoplasm | PROBABILISTIC | 0.70 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Palliative Treatment | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fully covered SEMS | Device | — | UNRESOLVED |
| Partially covered SEMS | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Partially covered SEMS
- description
- Boston Scientific Ultraflex SEMS
- interventionNames
- Device: Partially covered SEMS
- type
- EXPERIMENTAL
- label
- Fully covered SEMS
- description
- Boston Scientific Wallflex Esophageal SEMS.
- interventionNames
- Device: Fully covered SEMS
Primary outcomes (1)
- measure
- SEMS dislocation in cm during first thirty days after stent insertion.
- timeFrame
- Thirty days from stent deployment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Verified Squamous Cell Carcinoma or Adenocarcinoma of esophagus or Gastro Esophageal Junction (GEJ) * Age above 18 years. * Dysphagia scoring grade two or worse * Not amenable for curative treatment * Informed consent to participate Exclusion Criteria: * Concomitant cancer disease * Inability to comply with study protocol * Previous stent treatment * Proximal location of the tumour in the esophagus. * Need for more than one stent deployment.
References
Publications (0)
Data not yet available